Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

TGF-β induces PML SUMOylation, degradation and PML nuclear body disruption.

El-Asmi F, El-Mchichi B, Maroui MA, Dianoux L, Chelbi-Alix MK.

Cytokine. 2019 Aug;120:264-272. doi: 10.1016/j.cyto.2019.05.008. Epub 2019 May 29.

PMID:
31153006
2.

Rhabdoviruses, Antiviral Defense, and SUMO Pathway.

El Asmi F, Brantis-de-Carvalho CE, Blondel D, Chelbi-Alix MK.

Viruses. 2018 Dec 3;10(12). pii: E686. doi: 10.3390/v10120686. Review.

3.

[Modulation by SUMO of PKR activation and stability].

El Asmi F, Maarifi G, Ali Maroui M, Dianoux L, Chelbi-Alix MK.

Med Sci (Paris). 2018 Apr;34(4):285-288. doi: 10.1051/medsci/20183404002. Epub 2018 Apr 16. French. No abstract available.

4.

Promyelocytic Leukemia Protein (PML) Requirement for Interferon-induced Global Cellular SUMOylation.

Maroui MA, Maarifi G, McManus FP, Lamoliatte F, Thibault P, Chelbi-Alix MK.

Mol Cell Proteomics. 2018 Jun;17(6):1196-1208. doi: 10.1074/mcp.RA117.000447. Epub 2018 Mar 13.

5.

Differential effects of SUMO1 and SUMO3 on PKR activation and stability.

Maarifi G, El Asmi F, Maroui MA, Dianoux L, Chelbi-Alix MK.

Sci Rep. 2018 Jan 19;8(1):1277. doi: 10.1038/s41598-018-19683-6.

6.

Uncovering the SUMOylation and ubiquitylation crosstalk in human cells using sequential peptide immunopurification.

Lamoliatte F, McManus FP, Maarifi G, Chelbi-Alix MK, Thibault P.

Nat Commun. 2017 Jan 18;8:14109. doi: 10.1038/ncomms14109.

7.

MxA Mediates SUMO-Induced Resistance to Vesicular Stomatitis Virus.

Maarifi G, Hannoun Z, Geoffroy MC, El Asmi F, Zarrouk K, Nisole S, Blondel D, Chelbi-Alix MK.

J Virol. 2016 Jun 24;90(14):6598-6610. doi: 10.1128/JVI.00722-16. Print 2016 Jul 15.

8.

The implication of SUMO in intrinsic and innate immunity.

Hannoun Z, Maarifi G, Chelbi-Alix MK.

Cytokine Growth Factor Rev. 2016 Jun;29:3-16. doi: 10.1016/j.cytogfr.2016.04.003. Epub 2016 Apr 27. Review.

PMID:
27157810
9.

[SUMO paralogs and interferon response].

Maarifi G, Dianoux L, Nisole S, Chelbi-Alix MK.

Med Sci (Paris). 2016 Feb;32(2):141-3. doi: 10.1051/medsci/20163202002. Epub 2016 Mar 2. French. No abstract available.

10.

PML/TRIM19-Dependent Inhibition of Retroviral Reverse-Transcription by Daxx.

Dutrieux J, Maarifi G, Portilho DM, Arhel NJ, Chelbi-Alix MK, Nisole S.

PLoS Pathog. 2015 Nov 13;11(11):e1005280. doi: 10.1371/journal.ppat.1005280. eCollection 2015 Nov.

11.

Small Ubiquitin-like Modifier Alters IFN Response.

Maarifi G, Maroui MA, Dutrieux J, Dianoux L, Nisole S, Chelbi-Alix MK.

J Immunol. 2015 Sep 1;195(5):2312-24. doi: 10.4049/jimmunol.1500035. Epub 2015 Jul 29.

12.

Resistance to Rhabdoviridae Infection and Subversion of Antiviral Responses.

Blondel D, Maarifi G, Nisole S, Chelbi-Alix MK.

Viruses. 2015 Jul 7;7(7):3675-702. doi: 10.3390/v7072794. Review.

13.

MxA interacts with and is modified by the SUMOylation machinery.

Brantis-de-Carvalho CE, Maarifi G, Gonçalves Boldrin PE, Zanelli CF, Nisole S, Chelbi-Alix MK, Valentini SR.

Exp Cell Res. 2015 Jan 1;330(1):151-63. doi: 10.1016/j.yexcr.2014.10.020. Epub 2014 Oct 31.

PMID:
25447205
14.

Large-scale analysis of lysine SUMOylation by SUMO remnant immunoaffinity profiling.

Lamoliatte F, Caron D, Durette C, Mahrouche L, Maroui MA, Caron-Lizotte O, Bonneil E, Chelbi-Alix MK, Thibault P.

Nat Commun. 2014 Nov 13;5:5409. doi: 10.1038/ncomms6409.

PMID:
25391492
15.

Sodium arsenite induces apoptosis and Epstein-Barr virus reactivation in lymphoblastoid cells.

Zebboudj A, Maroui MA, Dutrieux J, Touil-Boukoffa C, Bourouba M, Chelbi-Alix MK, Nisole S.

Biochimie. 2014 Dec;107 Pt B:247-56. doi: 10.1016/j.biochi.2014.09.002. Epub 2014 Sep 21.

PMID:
25241256
16.

[Implication of PML nuclear bodies in intrinsic and innate immunity].

Maroui MA, El Asmi F, Dutrieux J, Chelbi-Alix MK, Nisole S.

Med Sci (Paris). 2014 Aug-Sep;30(8-9):765-71. doi: 10.1051/medsci/20143008014. Epub 2014 Sep 1. Review. French.

17.

PML control of cytokine signaling.

Maarifi G, Chelbi-Alix MK, Nisole S.

Cytokine Growth Factor Rev. 2014 Oct;25(5):551-61. doi: 10.1016/j.cytogfr.2014.04.008. Epub 2014 May 9. Review.

PMID:
24861946
18.

Implication of PMLIV in both intrinsic and innate immunity.

El Asmi F, Maroui MA, Dutrieux J, Blondel D, Nisole S, Chelbi-Alix MK.

PLoS Pathog. 2014 Feb 27;10(2):e1003975. doi: 10.1371/journal.ppat.1003975. eCollection 2014 Feb.

19.

Differential Roles of PML Isoforms.

Nisole S, Maroui MA, Mascle XH, Aubry M, Chelbi-Alix MK.

Front Oncol. 2013 May 22;3:125. doi: 10.3389/fonc.2013.00125. eCollection 2013.

20.

Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms.

Maroui MA, Kheddache-Atmane S, El Asmi F, Dianoux L, Aubry M, Chelbi-Alix MK.

PLoS One. 2012;7(9):e44949. doi: 10.1371/journal.pone.0044949. Epub 2012 Sep 18.

21.

Promyelocytic leukemia isoform IV confers resistance to encephalomyocarditis virus via the sequestration of 3D polymerase in nuclear bodies.

Maroui MA, Pampin M, Chelbi-Alix MK.

J Virol. 2011 Dec;85(24):13164-73. doi: 10.1128/JVI.05808-11. Epub 2011 Oct 12.

22.

Role of promyelocytic leukemia protein in host antiviral defense.

Geoffroy MC, Chelbi-Alix MK.

J Interferon Cytokine Res. 2011 Jan;31(1):145-58. doi: 10.1089/jir.2010.0111. Epub 2011 Jan 3. Review.

PMID:
21198351
23.

PML positively regulates interferon gamma signaling.

El Bougrini J, Dianoux L, Chelbi-Alix MK.

Biochimie. 2011 Mar;93(3):389-98. doi: 10.1016/j.biochi.2010.11.005. Epub 2010 Nov 27.

PMID:
21115099
24.

A novel proteomics approach to identify SUMOylated proteins and their modification sites in human cells.

Galisson F, Mahrouche L, Courcelles M, Bonneil E, Meloche S, Chelbi-Alix MK, Thibault P.

Mol Cell Proteomics. 2011 Feb;10(2):M110.004796. doi: 10.1074/mcp.M110.004796. Epub 2010 Nov 22.

25.

SUMOylation promotes PML degradation during encephalomyocarditis virus infection.

El McHichi B, Regad T, Maroui MA, Rodriguez MS, Aminev A, Gerbaud S, Escriou N, Dianoux L, Chelbi-Alix MK.

J Virol. 2010 Nov;84(22):11634-45. doi: 10.1128/JVI.01321-10. Epub 2010 Sep 8.

26.

Resistance to rabies virus infection conferred by the PMLIV isoform.

Blondel D, Kheddache S, Lahaye X, Dianoux L, Chelbi-Alix MK.

J Virol. 2010 Oct;84(20):10719-26. doi: 10.1128/JVI.01286-10. Epub 2010 Aug 11.

27.

Arsenic trioxide reduces 2,4,6-trinitrobenzene sulfonic acid-induced murine colitis via nuclear factor-κB down-regulation and caspase-3 activation.

Singer M, Trugnan G, Chelbi-Alix MK.

Innate Immun. 2011 Aug;17(4):365-74. doi: 10.1177/1753425910371668. Epub 2010 Aug 6.

PMID:
20693187
28.

Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.

Percherancier Y, Germain-Desprez D, Galisson F, Mascle XH, Dianoux L, Estephan P, Chelbi-Alix MK, Aubry M.

J Biol Chem. 2009 Jun 12;284(24):16595-608. doi: 10.1074/jbc.M109.006387. Epub 2009 Apr 20.

29.

[New therapeutic perspectives for arsenic: from acute promyelocytic leukemia to autoimmune diseases].

Bobé P, Chelbi-Alix MK.

Med Sci (Paris). 2008 Nov;24(11):967-71. doi: 10.1051/medsci/20082411967. French.

30.

Novel function of STAT1beta in B cells: induction of cell death by a mechanism different from that of STAT1alpha.

Najjar I, Schischmanoff PO, Baran-Marszak F, Deglesne PA, Youlyouz-Marfak I, Pampin M, Feuillard J, Bornkamm GW, Chelbi-Alix MK, Fagard R.

J Leukoc Biol. 2008 Dec;84(6):1604-12. doi: 10.1189/jlb.0508287. Epub 2008 Sep 11.

PMID:
18753311
31.

Implication of TRIM alpha and TRIMCyp in interferon-induced anti-retroviral restriction activities.

Carthagena L, Parise MC, Ringeard M, Chelbi-Alix MK, Hazan U, Nisole S.

Retrovirology. 2008 Jul 9;5:59. doi: 10.1186/1742-4690-5-59.

32.

Interferon, a growing cytokine family: 50 years of interferon research.

Chelbi-Alix MK, Wietzerbin J.

Biochimie. 2007 Jun-Jul;89(6-7):713-8. Epub 2007 May 10. Review.

PMID:
17544197
33.

PML and PML nuclear bodies: implications in antiviral defence.

Everett RD, Chelbi-Alix MK.

Biochimie. 2007 Jun-Jul;89(6-7):819-30. Epub 2007 Jan 27. Review.

PMID:
17343971
34.
35.

Transcriptional profiling reveals a possible role for the timing of the inflammatory response in determining susceptibility to a viral infection.

Ruby T, Whittaker C, Withers DR, Chelbi-Alix MK, Morin V, Oudin A, Young JR, Zoorob R.

J Virol. 2006 Sep;80(18):9207-16.

36.

Arsenic trioxide: A promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice.

Bobé P, Bonardelle D, Benihoud K, Opolon P, Chelbi-Alix MK.

Blood. 2006 Dec 15;108(13):3967-75. Epub 2006 Aug 22.

PMID:
16926289
37.

Arsenic enhances the apoptosis induced by interferon gamma: key role of IRF-1.

El Bougrini J, Pampin M, Chelbi-Alix MK.

Cell Mol Biol (Noisy-le-grand). 2006 May 15;52(1):9-15.

PMID:
16914093
38.

Cross talk between PML and p53 during poliovirus infection: implications for antiviral defense.

Pampin M, Simonin Y, Blondel B, Percherancier Y, Chelbi-Alix MK.

J Virol. 2006 Sep;80(17):8582-92.

39.

Rabies viral mechanisms to escape the IFN system: the viral protein P interferes with IRF-3, Stat1, and PML nuclear bodies.

Chelbi-Alix MK, Vidy A, El Bougrini J, Blondel D.

J Interferon Cytokine Res. 2006 May;26(5):271-80. Review.

PMID:
16689655
40.

The exonuclease ISG20 mainly localizes in the nucleolus and the Cajal (Coiled) bodies and is associated with nuclear SMN protein-containing complexes.

Espert L, Eldin P, Gongora C, Bayard B, Harper F, Chelbi-Alix MK, Bertrand E, Degols G, Mechti N.

J Cell Biochem. 2006 Aug 1;98(5):1320-33.

PMID:
16514659
41.

[Negative regulation of the JAK/STAT: pathway implication in tumorigenesis].

Espert L, Dusanter-Fourt I, Chelbi-Alix MK.

Bull Cancer. 2005 Oct;92(10):845-57. French.

42.

An essential role for IFN-alpha in the overexpression of Fas ligand on MRL/lpr lymphocytes and on their spontaneous Fas-mediated cytotoxic potential.

Hadj-Slimane R, Chelbi-Alix MK, Tovey MG, Bobé P.

J Interferon Cytokine Res. 2004 Dec;24(12):717-28.

PMID:
15684739
43.

Interferons alpha and gamma induce p53-dependent and p53-independent apoptosis, respectively.

Porta C, Hadj-Slimane R, Nejmeddine M, Pampin M, Tovey MG, Espert L, Alvarez S, Chelbi-Alix MK.

Oncogene. 2005 Jan 20;24(4):605-15.

PMID:
15580300
44.

The exonuclease ISG20 is directly induced by synthetic dsRNA via NF-kappaB and IRF1 activation.

Espert L, Rey C, Gonzalez L, Degols G, Chelbi-Alix MK, Mechti N, Gongora C.

Oncogene. 2004 Jun 3;23(26):4636-40.

PMID:
15064705
45.

Arsenic enhances the activation of Stat1 by interferon gamma leading to synergistic expression of IRF-1.

Chelbi-alix MK, Bobé P, Benoit G, Canova A, Pine R.

Oncogene. 2003 Dec 11;22(57):9121-30.

PMID:
14668793
46.

Rabies virus P and small P products interact directly with PML and reorganize PML nuclear bodies.

Blondel D, Regad T, Poisson N, Pavie B, Harper F, Pandolfi PP, De Thé H, Chelbi-Alix MK.

Oncogene. 2002 Nov 14;21(52):7957-70.

47.

Role and fate of PML nuclear bodies in response to interferon and viral infections.

Regad T, Chelbi-Alix MK.

Oncogene. 2001 Oct 29;20(49):7274-86. Review.

48.

APL, a model disease for cancer therapies?

de Thé H, Chelbi-Alix MK.

Oncogene. 2001 Oct 29;20(49):7136-9. Review. No abstract available.

49.

PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator.

Regad T, Saib A, Lallemand-Breitenbach V, Pandolfi PP, de Thé H, Chelbi-Alix MK.

EMBO J. 2001 Jul 2;20(13):3495-505.

50.

Interferon-beta induces S phase slowing via up-regulated expression of PML in squamous carcinoma cells.

Vannucchi S, Percario ZA, Chiantore MV, Matarrese P, Chelbi-Alix MK, Fagioli M, Pelicci PG, Malorni W, Fiorucci G, Romeo G, Affabris E.

Oncogene. 2000 Oct 19;19(44):5041-53.

Supplemental Content

Loading ...
Support Center